Literature DB >> 17059894

Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program.

Peter Achenbach1, Michael Schlosser, Alistair J K Williams, Liping Yu, Patricia W Mueller, Polly J Bingley, Ezio Bonifacio.   

Abstract

The aim of the workshop was to assess whether four laboratories could reproducibly measure insulin autoantibody (IAA) affinity in coded sera from non-diabetic relatives of patients with type 1 diabetes, newly diagnosed patients, and healthy blood donors, and whether combining affinity with autoantibody titer could improve concordance and performance of IAA assays. IAA affinity was measured by competitive binding using constant amounts of Tyr14A [125I] human insulin and increasing quantities of unlabeled human insulin. There was high concordance between laboratories in distinguishing high, moderate, and low affinity IAA, although IAA binding to insulin varied with assay format. Multiple islet autoantibody-positive and patient sera were identified by high affinity IAA regardless of laboratory-designated IAA status. Combining affinity and titer significantly improved sensitivity, specificity, and concordance of IAA measurement. This workshop has demonstrated that different laboratories are able to reproduce IAA affinity results and that considering IAA affinity is likely to improve the diagnostic performance of IAA assays.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059894     DOI: 10.1016/j.clim.2006.09.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  18 in total

1.  Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies.

Authors:  M Schlosser; P W Mueller; C Törn; E Bonifacio; P J Bingley
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 2.  Clinical and Laboratory Aspects of Insulin Autoantibody-Mediated Glycaemic Dysregulation and Hyperinsulinaemic Hypoglycaemia: Insulin Autoimmune Syndrome and Exogenous Insulin Antibody Syndrome.

Authors:  Tony Huynh
Journal:  Clin Biochem Rev       Date:  2020-12

3.  'Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes.

Authors:  R M Curnock; C R Reed; S Rokni; J W Broadhurst; P J Bingley; A J K Williams
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

4.  Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects.

Authors:  J M Wenzlau; M Walter; T J Gardner; L M Frisch; L Yu; G S Eisenbarth; A-G Ziegler; H W Davidson; J C Hutton
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

Review 5.  Prediction and pathogenesis in type 1 diabetes.

Authors:  Anette-G Ziegler; Gerald T Nepom
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

6.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

7.  Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.

Authors:  George S Eisenbarth
Journal:  Diabetes       Date:  2010-04       Impact factor: 9.461

8.  A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.

Authors:  Bo Zhang; Rajiv B Kumar; Hongjie Dai; Brian J Feldman
Journal:  Nat Med       Date:  2014-07-13       Impact factor: 53.440

9.  Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2.

Authors:  C Törn; P W Mueller; M Schlosser; E Bonifacio; P J Bingley
Journal:  Diabetologia       Date:  2008-03-29       Impact factor: 10.122

Review 10.  Islet Autoantibodies.

Authors:  Vito Lampasona; Daniela Liberati
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.